Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
Vir Biotechnology will present complete Week 96 data from its Phase 2 SOLSTICE trial for chronic hepatitis delta at the EASL Congress 2026 in Barcelona. The oral presentation, selected as 'Best of EASL 2026,' covers the efficacy and safety of tobevibart alone or in combination with elebsiran.
Key figures
- Drug Name
- tobevibart (VIR-3434) and elebsiran (VIR-2218)
- Phase Of Trial
- Phase 2
- Conference
- EASL Congress 2026
- Trial name
- SOLSTICE
- Data timepoint
- Week 96
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.